中文摘要：

目的探讨三伏贴对妊娠期哮喘慢性持续期患者的治疗效果。方法选取2010年1月—2014年1月到华北理工大学附属医院就诊的妊娠期哮喘慢性持续期患者120例。按照随机数字表法,将其分为对照组和试验组各60例。对照组采用布地奈德雾化吸入治疗,试验组在对照组的治疗基础上加用三伏贴治疗。分别于治疗前和试验组末次贴敷结束10 d后,检测两组肺功能、炎性因子及相关因素水平,同时记录两组临床疗效和不良反应发生情况。结果对照组有57例完成了治疗,试验组58例,两组平均年龄、平均病程及疾病程度比较,差异无统计学意义（P〉0.05）。治疗前两组第1秒用力呼气末容积（FEV1）、呼气峰流量（PEF）、FEV_1与用力肺活量比值（FEV_1/FVC）比较,差异无统计学意义（P〉0.05）;治疗后两组FEV_1、PEF及FEV_1/FVC比较,差异有统计学意义（P〈0.05）;治疗后两组FEV_1、PEF及FEV_1/FVC与治疗前比较,差异均有统计学意义（P〈0.05）。治疗前两组血清转化生长因子β_1（TGF-β_1）、肿瘤坏死因子α（INF-α）、γ-干扰素（IFN-γ）、辅助性T细胞（Th17）、皮质醇及瘦素水平比较,差异无统计学意义（P〉0.05）。治疗后两组血清TGF-β_1、INF-α、IFN-γ、Th17、皮质醇及瘦素水平比较,差异有统计学意义（P〈0.05）。治疗后两组血清TGF-β_1、INF-α、IFN-γ、Th17、皮质醇及瘦素水平与治疗前比较,差异均有统计学意义（P〈0.05）。两组临床疗效比较,差异有统计学意义（P〈0.05）。两组不良反应发生率比较,差异无统计学意义（P〉0.05）。结论三伏贴治疗妊娠期哮喘慢性持续期的临床疗效确切,可以改善患者肺功能、血清炎性因子及相关因素水平,且不良反应较少。

英文摘要：

Objective To investigate the efficacy of dog-days paste on pregnant patients with asthma in chronic persistent period. Methods We enrolled 120 pregnant patients with asthma in chronic persistent period who were treated in the Affiliated Hospital to the North China University of Science and Technology from January 2010 to January 2014. Using random number table method,we divided the subjects into two groups： control group（ n = 60） and trial group（ n = 60）. Control group was administrated with budesonide atomization inhalation treatment,and trial group was administrated with dog-days paste on the basis of budesonide atomization inhalation treatment. Before treatment and 10 days after the last application of dog-days paste,pulmonary function,inflammatory factor and relevant factors of the two groups were detected,and the clinical efficacy and adverse reactions were recorded. Results There were 57 patients in control group and 58 patients in trial group who completed the treatment. The two groups were not significantly different in average age,average length of disease and degree of disease（ P 〉0. 05）. Before treatment,the two groups were not significantly different in FEV_1,PEF and FEV_1/ FVC（ P 〉0. 05）; after treatment, the two groups were significantly different in FEV_1, PEF and FEV_1/ FVC（ P 〉0. 05）; after treatment,FEV_1,PEF and FEV_1/ FVC of the two groups were significantly different from those before treatment（ P 〈0. 05）;Before treatment,the two groups were not significantly different in TGF-β_1,INF-α,IFN-γ,Th17,cortisol and leptin level（ P 〈0. 05）; after treatment,the two groups were significantly different in TGF-β_1,TNF-α,IFN-γ,Th17,cortisol and leptin（ P 〈0. 05）; after treatment, TGF-β_1,INF-α,IFN-γ,Th17,cortisol and leptin level of the two groups were significantly different from those before treatment（ P 〈0. 05）. The two groups were significantly different in clinical efficacy（ P 〈0. 05）. The two groups were not significantly different